These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

258 related items for PubMed ID: 10350376

  • 1. Prediction of the antimicrobial effects of trovafloxacin and ciprofloxacin on staphylococci using an in-vitro dynamic model.
    Firsov AA, Vasilov RG, Vostrov SN, Kononenko OV, Lubenko IY, Zinner SH.
    J Antimicrob Chemother; 1999 Apr; 43(4):483-90. PubMed ID: 10350376
    [Abstract] [Full Text] [Related]

  • 2. Prediction of the effects of inoculum size on the antimicrobial action of trovafloxacin and ciprofloxacin against Staphylococcus aureus and Escherichia coli in an in vitro dynamic model.
    Firsov AA, Vostrov SN, Kononenko OV, Zinner SH, Portnoy YA.
    Antimicrob Agents Chemother; 1999 Mar; 43(3):498-502. PubMed ID: 10049257
    [Abstract] [Full Text] [Related]

  • 3. A new approach to in vitro comparisons of antibiotics in dynamic models: equivalent area under the curve/MIC breakpoints and equiefficient doses of trovafloxacin and ciprofloxacin against bacteria of similar susceptibilities.
    Firsov AA, Vostrov SN, Shevchenko AA, Portnoy YA, Zinner SH.
    Antimicrob Agents Chemother; 1998 Nov; 42(11):2841-7. PubMed ID: 9797213
    [Abstract] [Full Text] [Related]

  • 4. Bacterial strain-independent AUC/MIC and strain-specific dose-response relationships reflecting comparative fluoroquinolone anti-pseudomonal pharmacodynamics in an in vitro dynamic model.
    Lubenko IY, Vostrov SN, Portnoy YA, Zinner SH, Firsov AA.
    Int J Antimicrob Agents; 2002 Jul; 20(1):44-9. PubMed ID: 12127710
    [Abstract] [Full Text] [Related]

  • 5. Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and equiefficient doses.
    Firsov AA, Lubenko IY, Vostrov SN, Kononenko OV, Zinner SH, Portnoy YA.
    J Antimicrob Chemother; 2000 Nov; 46(5):725-32. PubMed ID: 11062191
    [Abstract] [Full Text] [Related]

  • 6. Comparative anti-staphylococcal effects of gemifloxacin and trovafloxacin in an in vitro dynamic model in terms of AUC/MIC and dose relationships.
    Zinner SH, Vostrov SN, Lubenko IY, Portnoy YA, Cornaglia G, Firsov AA.
    Diagn Microbiol Infect Dis; 2001 Aug; 40(4):167-71. PubMed ID: 11576789
    [Abstract] [Full Text] [Related]

  • 7. Gemifloxacin and ciprofloxacin pharmacodynamics in an in-vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and doses.
    Firsov AA, Zinner SH, Lubenko IYu, Vostrov SN.
    Int J Antimicrob Agents; 2000 Dec; 16(4):407-14. PubMed ID: 11118849
    [Abstract] [Full Text] [Related]

  • 8. Comparative pharmacodynamics of gatifloxacin and ciprofloxacin in an in vitro dynamic model: prediction of equiefficient doses and the breakpoints of the area under the curve/MIC ratio.
    Vostrov SN, Kononenko OV, Lubenko IY, Zinner SH, Firsov AA.
    Antimicrob Agents Chemother; 2000 Apr; 44(4):879-84. PubMed ID: 10722485
    [Abstract] [Full Text] [Related]

  • 9. Inter- and intraquinolone predictors of antimicrobial effect in an in vitro dynamic model: new insight into a widely used concept.
    Firsov AA, Shevchenko AA, Vostrov SN, Zinner SH.
    Antimicrob Agents Chemother; 1998 Mar; 42(3):659-65. PubMed ID: 9517948
    [Abstract] [Full Text] [Related]

  • 10. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and ciprofloxacin with Escherichia coli and Pseudomonas aeruginosa in an in vitro dynamic model.
    Zinner SH, Vostrov SN, Alferova IV, Lubenko IY, Portnoy YA, Firsov AA.
    Int J Antimicrob Agents; 2004 Aug; 24(2):173-7. PubMed ID: 15288317
    [Abstract] [Full Text] [Related]

  • 11. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.
    Gootz TD, Zaniewski RP, Haskell SL, Kaczmarek FS, Maurice AE.
    Antimicrob Agents Chemother; 1999 Aug; 43(8):1845-55. PubMed ID: 10428901
    [Abstract] [Full Text] [Related]

  • 12. Phenotypic resistance of Staphylococcus aureus, selected Enterobacteriaceae, and Pseudomonas aeruginosa after single and multiple in vitro exposures to ciprofloxacin, levofloxacin, and trovafloxacin.
    Gilbert DN, Kohlhepp SJ, Slama KA, Grunkemeier G, Lewis G, Dworkin RJ, Slaughter SE, Leggett JE.
    Antimicrob Agents Chemother; 2001 Mar; 45(3):883-92. PubMed ID: 11181375
    [Abstract] [Full Text] [Related]

  • 13. MIC-based interspecies prediction of the antimicrobial effects of ciprofloxacin on bacteria of different susceptibilities in an in vitro dynamic model.
    Firsov AA, Vostrov SN, Shevchenko AA, Zinner SH, Cornaglia G, Portnoy YA.
    Antimicrob Agents Chemother; 1998 Nov; 42(11):2848-52. PubMed ID: 9797214
    [Abstract] [Full Text] [Related]

  • 14. Antistaphylococcal effect related to the area under the curve/MIC ratio in an in vitro dynamic model: predicted breakpoints versus clinically achievable values for seven fluoroquinolones.
    Firsov AA, Lubenko IY, Vostrov SN, Portnoy YA, Zinner SH.
    Antimicrob Agents Chemother; 2005 Jul; 49(7):2642-7. PubMed ID: 15980331
    [Abstract] [Full Text] [Related]

  • 15. Species-independent pharmacodynamics of gemifloxacin and ciprofloxacin with Haemophilus influenzae and Moraxella catarrhalis in an in vitro dynamic model.
    Portnoy YA, Vostrov SN, Lubenko IY, Zinner SH, Firsov AA.
    Int J Antimicrob Agents; 2002 Sep; 20(3):201-5. PubMed ID: 12385699
    [Abstract] [Full Text] [Related]

  • 16. In-vitro activity of clinafloxacin, trovafloxacin, and ciprofloxacin.
    Cohen MA, Huband MD, Gage JW, Yoder SL, Roland GE, Gracheck SJ.
    J Antimicrob Chemother; 1997 Aug; 40(2):205-11. PubMed ID: 9301985
    [Abstract] [Full Text] [Related]

  • 17. The pharmacodynamics of gatifloxacin and ciprofloxacin for pneumococci in an in vitro dynamic model: prediction of equiefficient doses.
    Zinner SH, Firsov AA, Gilbert D, Simmons K, Lubenko IY.
    J Antimicrob Chemother; 2001 Dec; 48(6):821-6. PubMed ID: 11733466
    [Abstract] [Full Text] [Related]

  • 18. Comparative in-vitro activities of trovafloxacin, ciproflaxacin, ofloxacin, and broad-spectrum beta-lactams against aerobe blood culture isolates.
    Seifert H.
    Zentralbl Bakteriol; 1998 Dec; 288(4):509-18. PubMed ID: 9987189
    [Abstract] [Full Text] [Related]

  • 19. Antibacterial activity of trovafloxacin against nosocomial Gram-positive and Gram-negative isolates.
    Cunha BA, Qadri SM, Ueno Y, Walters EA, Domenico P.
    J Antimicrob Chemother; 1997 Jun; 39 Suppl B():29-34. PubMed ID: 9222067
    [Abstract] [Full Text] [Related]

  • 20. Pharmacodynamic studies of trovafloxacin and grepafloxacin in vitro against Gram-positive and Gram-negative bacteria.
    Odenholt I, Cars T, Lowdin E.
    J Antimicrob Chemother; 2000 Jul; 46(1):35-43. PubMed ID: 10882686
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.